TEST CATALOG ORDERING & RESULTS SPECIMEN HANDLING CUSTOMER SERVICE EDUCATION & INSIGHTS
Test Catalog

Test ID: GATA3    
GATA Binding Protein 3 Immunostain, Technical Component Only

Useful For Suggests clinical disorders or settings where the test may be helpful

Characterizing carcinomas, including primary bladder and breast carcinomas, and some types of mesenchymal and neuroectodermal tumors

Testing Algorithm Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

For the initial technical component only immunohistochemical (IHC) stain performed, the appropriate bill-only test ID will be reflexed and charged (IHTOI). For each additional technical component only IHC stain performed, an additional bill-only test ID will be reflexed and charged (IHTOA).

Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

GATA-binding protein 3 (GATA3) is a transcription factor of the GATA family. GATA3 is involved in the regulation of development and differentiation of a variety of human tissues including T cells, skin, kidney, mammary gland, and the central nervous system. GATA3 has been shown to be a useful in the characterization of carcinomas, including primary bladder and breast carcinomas, and some types of mesenchymal and neuroectodermal tumors (ie, paragangliomas).

Interpretation Provides information to assist in interpretation of the test results

This test includes only technical performance of the stain (no pathologist interpretation is performed). Mayo Clinic cannot provide an interpretation of tech only stains outside the context of a pathology consultation. If an interpretation is needed, refer to PATHC / Pathology Consultation for a full diagnostic evaluation or second opinion of the case. All material associated with the case is required. Additional specific stains may be requested as part of the pathology consultation, and will be performed as necessary at the discretion of the Mayo pathologist.

 

The positive and negative controls are verified as showing appropriate immunoreactivity and documentation is retained at Mayo Clinic Rochester. If a control tissue is not included on the slide, a scanned image of the relevant quality control tissue is available upon request. Contact 855-516-8404.

 

Interpretation of this test should be performed in the context of the patient's clinical history and other diagnostic tests by a qualified pathologist.

Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

Age of a cut paraffin section can affect immunoreactivity. Stability thresholds vary widely among published literature and are antigen-dependent. Best practice is for paraffin sections to be cut fresh.

Clinical Reference Recommendations for in-depth reading of a clinical nature

1. Chang A, Amin A, Gabrielson E, et al: Utility of GATA3 immunohistochemistry in differentiating urothelial carcinoma from prostate adenocarcinoma and squamous cell carcinomas of the uterine cervix, anus, and Lung. Am J Surg Pathol 2012;36(10):1472-1476

2. Gruver AM, Amin MB, Luthringer DJ, et al: Selective immunohistochemical markers to distinguish between metastatic high-grade urothelial carcinoma and primary poorly differentiated invasive squamous cell carcinoma of the lung. Arch Pathol Lab Med 2010;136:1339-1346

3. Higgins JPT, Kaygusuz G, Wange L, et al: Placental S100(S100P) and GATA3: Markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray. Am J Surg Pathol 2007;31(5):673-680

4. Liu H, Shi J, Wilkerson ML, et al: Immunohistochemical evaluation of GATA3 expression in tumors and normal tissues. A useful immunomarker for breast and urothelial carcinomas. Am J Clin Pathol 2012;138:57-64

5. Miettinen M, McCue PA, Sarlomo-Rikala M, et al: GATA3: A Multispecific but potentially useful marker in surgical pathology. A systematic analysis of 2500 epithelial and nonepithelial tumors. Am J Surg Pathol 2014;38(1):13-22